Drug Trial Radar · NCT06071143
Safety and Efficacy of KDSTEM Inj. in Patients With Chronic Kidney Disease
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Feb 29, 2024
Primary completion
Mar 9, 2026
Study completion Mar 9, 2026
Sponsor
- Lead sponsor
- EHL Bio Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Single arm, Open-labelled, Dose-escalation, Single-center, Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Autologous Urine-derived Stem Cells, 『KDSTEM Inj.』, in Patients with Chronic Kidney Disease. The aim of this study is to evaluate the safety and preliminary efficacy of KDSTEM Inj. in the treatment in Patients with Chronic Kidney Disease.
Conditions
- Chronic Kidney Diseases
Interventions
KDSTEM Inj.Biological
1. Low dose: The following study drugs are pre-mixed with 90mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 1.0x10\^8 cells/10mL/2 syringes) 2. High dose: The following study drugs are pre-mixed with 70mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 3.0x10\^8 cells/30mL/6 syringes)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of subjects with treatment-related adverse events as assessed by CTCAE version 5.0Time frame: 28 weeks follow-up after first injection
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chungnam National University Hospital
Daejeon, Chungcheongnam-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.